Aura Biosciences, Inc. (AURA) Stock Ticker
AURA right now
Market factors today
Unlock the full AURA picture
About Aura Biosciences, Inc.
Headquartered in Cambridge, Massachusetts, Aura Biosciences, Inc. is a biotechnology firm established in 2009 that specializes in pioneering cancer treatments. The company leverages its proprietary virus-like drug conjugate (VDC) technology platform to address tumors with significant unmet medical needs, specifically in ocular (eye) and urologic oncology. Its flagship therapeutic candidate, AU-011, is a VDC currently in development for the treatment of primary choroidal melanoma. Furthermore, Aura Biosciences is investigating AU-011's potential for other ocular oncology applications, such as choroidal metastases.
AURA stock facts
| Ticker symbol | AURA |
| Exchange | NASDAQ Global Market |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market cap | $620.6M |
| CEO | Natalie C. Holles |
| Employees | 113 |
| Headquarters | Boston, MA, US |
| IPO date | 2021-10-29 |
| Website | www.aurabiosciences.com |
What you can see for AURA on Tickr
Live AURA price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the AURA report.
Rankings
FAQ
What is the ticker symbol for Aura Biosciences, Inc.?
The ticker symbol for Aura Biosciences, Inc. is AURA, listed on the NASDAQ Global Market.
What is AURA?
Headquartered in Cambridge, Massachusetts, Aura Biosciences, Inc. is a biotechnology firm established in 2009 that specializes in pioneering cancer treatments. The company leverages its proprietary virus-like drug conjugate (VDC) technology platform to address tumors with significant unmet medical needs, specifically in ocular (eye) and urologic oncology. Its flagship therapeutic candidate,…